Clinical Trial Update: MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon [Phase 4]

View source ↗

Summary

Phase 4 MIRAGE study evaluating the Mamba sirolimus-eluting PTCA balloon for coronary artery disease has completed, reporting clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Atherosclerotic Cardiovascular Disease
• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Mamba Sirolimus-Eluting PTCA Balloon
• Sirolimus (Sirolimus)

Snippet

Sponsor: Frisch Medical Device Private Limited | Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | Phase 4 | Status: COMPLETED